Biggest News Aggregation in the World
📰 Clinical Program News

Page 20 - Clinical Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Clinical Program. Real-time updates on events, politics, business and more.

Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death -- -- UPLIZNA is indicated as monotherapy for
Republic Of Republic Of China Taiwan General South Korea M Neuromyelitis Optica Correalej Neuromyelitis

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) - read this article along with other careers information, tips and advice on BioSpace
Republic Of South Korea Republic Of China Taiwan General M Neuromyelitis Optica Neuroimmunol Neuroinflamm

Takeda's TAKHZYRO&#xAE; (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)

SHP643-301 is A Multicenter, Open-Label Phase 3 Study to Evaluate Safety, PK, Pharmacodynamics, And Clinical Activity/Outcomes of TAKHZYRO for Prevention…
United States Clinical Program For Patients European Union Summary Of Product Characteristics Takeda Pharmaceutical Company Limited Open Label Phase Met Its Objectives
Source: canada.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science